KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.

Jessica L Fleming, Stephanie L Pugh, Susan M Chang, Joseph P McElroy, Aline P Becker, Kenneth D Aldape, Helen A Shih, Lynn Stuart Ashby, Grant K Hunter, Jean-Paul Bahary, Christopher J Schultz, Brian D Kavanagh, Vinay K Puduvalli, H Ian Robins, Maria Werner-Wasik, Minesh Mehta, Arnab Chakravarti

Int J Radiat Oncol Biol Phys 123(1) 84-92

PMID40164352
PMCIDPMC12857254
DOI10.1016/j.ijrobp.2025.03.043
发表日期2025-03-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图。
摘要

摘要

PURPOSE: There is a need to better understand the molecular features that characterize grade 3 astrocytomas and their significance in predicting clinical outcomes. The aim of this study was to determine the significance of the 2021 World Health Organization (WHO)-defined molecular subgroups, along with MGMT promoter methylation, and other alterations in NRG Oncology/RTOG 9813. METHODS AND MATERIALS: Mutation status was determined by immunohistochemistry and/or next-generation sequencing. Copy number alterations and MGMT methylation were determined by Affymetrix Oncoscan and/or Illumina 450K arrays. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and tested using the log-rank test. Multivariable analyses used Cox proportional hazards models. RESULTS: Application of the 2021 WHO-defined criteria resulted in the reclassification of 26/79 (33%) patients to grade 4 astrocytoma, IDH-mutant or glioblastoma. When looking at newly assigned molecular grade, grade 3 patients experienced longer survival outcomes compared to grade 4 patients. As individual biomarkers, IDH1/2 mutations, MGMT promoter methylation, and ATRX mutations were each associated with longer survival, whereas TERT promoter mutations, EGFR amplification, and gain of chromosome 7/loss of 10 (Chr+7/-10) were associated with shorter survival. Similar survival outcomes were observed for MGMT methylated patients treated with radiation therapy (RT) and temozolomide (TMZ) or RT and BCNU/CCNU, and MGMT unmethylated patients treated with RT and TMZ. Additionally, IDH-mutant patients seemed to respond well to the addition of TMZ. CONCLUSIONS: This study demonstrated the importance of classifying patients according to the 2021 WHO-defined criteria. The majority of IDH-wildtype anaplastic astrocytomas (grade 3) were reclassified as glioblastoma (grade 4). These analyses also shed light on the efficacy of TMZ in certain molecular subgroups, where the addition of TMZ to RT appeared to benefit patients regardless of MGMT methylation status.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Molecular landscape in NRG Oncology/RTOG 9813. A summary of the molecular findings in NRG Oncology/RTOG 9813 patients (n = 113), along with select clinical data including age, sex, and histology. The top row shows the classification of patients into the 2021 WHO-defined molecular subgroups (Oligodendroglioma, grade 3; Astrocytoma, IDH -mutant, grade 3; Astrocytoma, IDH -mutant, grade 4; Astrocytoma, IDH -wildtype, NEC, grade 3, and Glioblastoma). Patients with incomplete molecular data were categorized as Unclassified. Mutation status for IDH1 , IDH2 , TERT promoter, ATRX , TP53 , CIC , and FUBP1 is displayed as mutated (red) or non-mutated (gray). The presence of the following copy number alterations is indicated in blue, 1p/19q co-deletion, CDKN2A/B homozygous deletion, EGFR amplification, and gain of whole chromosome 7 and loss of 10 (Chr+7/−10), whereas absence is in gray. MGMT promoter status is shown as methylated (green) or unmethylated (gray). Not determined (ND) indicates when data was not obtained for a patient (white). Molecular data was not obtained on 3/116 patients and were excluded from the molecular landscape figure. Abbreviations: IHC, immunohistochemistry; NEC, not elsewhere classified.
非 KM Figure
Figure 2.Survival by IDH1/2 mutation status. Kaplan-Meier survival plots show that patients with an IDH1/2- mutant tumor experienced significantly longer overall survival (A) and progression-free survival (B) times compared to patients with IDH1/2 -wildtype tumors.
非 KM Figure
Figure 3.Survival by MGMT promoter methylation status. Kaplan-Meier survival plots show that patients with MGMT methylated tumors experienced longer overall survival (A) and progression-free survival (B) times compared to patients with MGMT unmethylated tumors.
非 KM Figure
Figure 4.Treatment-specific effect of MGMT promoter methylation status and survival. Kaplan-Meier survival plots demonstrate that MGMT methylated patients treated with radiotherapy (RT) plus temozolomide (TMZ) or RT plus BCNU/CCNU experienced similar overall survival (A) and progression-free survival times (B). Patients with MGMT unmethylated tumors treated with RT and BCNU/CCNU had shorter overall survival (C) and progression-free survival (D) times compared to those treated with RT and TMZ.
非 KM Figure